Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group purchased a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 200,000 shares of the company's stock, valued at approximately $2,457,000. Syndax Pharmaceuticals accounts for about 1.3% of Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group's investment portfolio, making the stock its 18th biggest holding. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group owned approximately 0.23% of Syndax Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Soleus Capital Management L.P. boosted its stake in Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after buying an additional 1,401,016 shares in the last quarter. Sphera Funds Management LTD. boosted its stake in Syndax Pharmaceuticals by 33.5% during the fourth quarter. Sphera Funds Management LTD. now owns 1,381,241 shares of the company's stock worth $18,260,000 after buying an additional 346,395 shares in the last quarter. Granahan Investment Management LLC boosted its stake in Syndax Pharmaceuticals by 36.2% during the fourth quarter. Granahan Investment Management LLC now owns 905,322 shares of the company's stock worth $11,968,000 after buying an additional 240,557 shares in the last quarter. Octagon Capital Advisors LP acquired a new stake in Syndax Pharmaceuticals during the fourth quarter worth $11,951,000. Finally, Northern Trust Corp boosted its stake in Syndax Pharmaceuticals by 7.5% during the fourth quarter. Northern Trust Corp now owns 792,750 shares of the company's stock worth $10,480,000 after buying an additional 55,144 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SNDX. Guggenheim restated a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. UBS Group cut their price target on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, July 15th. The Goldman Sachs Group initiated coverage on Syndax Pharmaceuticals in a report on Thursday, July 10th. They issued a "buy" rating and a $18.00 price target for the company. Wall Street Zen raised Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. Finally, Scotiabank lifted their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $34.10.

Syndax Pharmaceuticals Stock Performance

SNDX stock traded up $0.27 during trading hours on Monday, hitting $9.73. 1,779,082 shares of the stock were exchanged, compared to its average volume of 1,873,636. The firm has a market capitalization of $837.27 million, a P/E ratio of -2.52 and a beta of 0.70. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $25.07. The company has a current ratio of 5.80, a quick ratio of 5.75 and a debt-to-equity ratio of 1.53. The company has a 50-day simple moving average of $9.86 and a two-hundred day simple moving average of $12.13.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. Syndax Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 757.53%. Syndax Pharmaceuticals's revenue was up 1900.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.85) earnings per share. On average, analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 7,534 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $9.29, for a total value of $69,990.86. Following the completion of the sale, the chief executive officer directly owned 298,661 shares in the company, valued at approximately $2,774,560.69. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).